ACADIA Pharmaceuticals (ACAD) Institutional Ownership

96.71% of ACADIA Pharmaceuticals' stock is owned by institutional investors. Learn more on ACAD's institutional investor holdings.

Of the 315 institutional investors that purchased ACADIA Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Norges Bank ($4.37M), Marshall Wace LLP ($4.28M), Assenagon Asset Management S.A. ($3.73M), SG Americas Securities LLC ($2.47M), Braidwell LP ($2.38M), Point72 Asset Management L.P. ($2.23M), and Millennium Management LLC ($2.20M).

Institutional investors have bought a total of 27,581,758 shares in the last 24 months. This purchase volume represents approximately $630.71M in transactions.

Of the 144 institutional investors that sold ACADIA Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Assenagon Asset Management S.A. ($3.65M), Adage Capital Partners GP L.L.C. ($2.48M), Marshall Wace LLP ($1.87M), Tang Capital Management LLC ($1.20M), Emerald Advisers LLC ($1.01M), Millennium Management LLC ($929.56K), and Fred Alger Management LLC ($827.49K).

Institutional investors have sold a total of 24,654,509 shares in the last 24 months. This volume of shares sold represents approximately $586.83M in transactions.